Press releases

Press release 2023/12/06

Medivir to present at the Carlsquare Equity Research Investor Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more

Press release 2023/12/01 Regulatory

Bulletin from Extraordinary General Meeting in Medivir AB (publ)

Today on 1 December 2023, Medivir AB (publ) (the “Company”) held an extraordinary general meeting in Stockholm, whereby the resolution below...

Read more

Press release 2023/11/27

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more

Press release 2023/11/22

Medivir to present at the Redeye Life Science Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more

Press release 2023/11/21

Medivir to present at the Erik Penser Bank Company Event

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more

Press release 2023/11/13

Medivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDA

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

Read more

Press release 2023/11/07 Regulatory

Notice of Extraordinary General Meeting in Medivir AB (publ)

The shareholders in Medivir AB (publ) reg. no. 556238-4361 (the “Company”) are hereby convened to the extraordinary general meeting, which will...

Read more

Press release 2023/11/07 Regulatory

Medivir announces a partially guaranteed rights issue of approximately SEK 148 million

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF...

Read more

Press release 2023/10/27 Regulatory

MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2023

“Updated data show that the combination fostrox + Lenvima® provides improved clinical efficacy compared to Lenvima study data alone in second-line...

Read more

Press release 2023/10/25

Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday

Webcasted Conference Call on Friday, October 27, 2023 at 14.00 CET Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical...

Read more

Press release 2023/10/23

Nomination Committee of Medivir appointed

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the nomination committee now has been appointed ahead of the...

Read more

Press release 2023/10/20 Regulatory

Change in Medivir's Board of Directors

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more